文献速递肿瘤 PET/CT核素与放射性配体治疗放射性药物与辐射防护

核医学与分子影像在妇科恶性肿瘤中的应用:综合综述

Nuclear Medicine and Molecular Imaging Applications in Gynecologic Malignancies: A Comprehensive Review.
PubMed 文献 · Semin Nucl Med · 2024-02-11

妇科恶性肿瘤(子宫内膜癌、宫颈癌、卵巢癌、外阴癌和阴道癌)诊断与治疗面临挑战,约19%的新诊断女性癌症为妇科来源。本文综述核医学在初始分期、淋巴结定位、疗效评估和复发监测中的作用,回顾18F-FDG PET/CT的局限性及PET/MRI的应用前景,并强调诊疗一体化应用及NCCN、ESGO和ESMO指南中的当前角色。

要点

  • 18F-FDG PET/CT结合代谢与解剖信息,已成为妇科肿瘤影像学不可或缺的工具。
  • 99mTc淋巴显像联合SPECT/CT用于前哨淋巴结识别,以减少广泛淋巴结清扫的手术并发症。
  • 治疗性核医学药物尚未成为妇科恶性肿瘤的标准方案,但为晚期或复发患者提供专门治疗选择。

核心结论

  • 核医学影像模态在妇科癌症的诊断检查和管理中的整合证据日益增多,18F-FDG PET/CT已成为肿瘤影像不可或缺的工具。

研究设计与样本

  • 本文为综合综述,旨在描述核医学在常见妇科癌症初始分期、淋巴结定位、疗效评估和复发/监测影像中的作用。

主要发现

  • 约19%的新诊断女性癌症为妇科来源。
  • 18F-FDG PET结合CT和MRI的解剖特异性,可混合评估代谢活动与结构异常。
  • 99mTc淋巴显像联合SPECT/CT在识别前哨淋巴结中起重要作用,以减少广泛淋巴结清扫的手术并发症。
  • 治疗性核医学药物尚未成为妇科恶性肿瘤的标准,但为晚期或复发疾病患者提供专门治疗选择。

关键数值与推荐

  • 本文根据NCCN、ESGO和ESMO指南强调核医学影像在妇科癌症中的当前作用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gynecologic malignancies, consisting of endometrial, cervical, ovarian, vulvar, and vaginal cancers, pose significant diagnostic and management challenges due to their complex anatomic location and potential for rapid progression. These tumors cause substantial morbidity and mortality, often because of their delayed diagnosis and treatment. An estimated 19% of newly diagnosed cancers among women are gynecologic in origin. In recent years, there has been growing evidence supporting the integration of nuclear medicine imaging modalities in the diagnostic work-up and management of gynecologic cancers. The sensitivity of fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG PET) combined with the anatomical specificity of computed tomography (CT) and magnetic resonance imaging (MRI) allows for the hybrid evaluation of metabolic activity and structural abnormalities that has become an indispensable tool in oncologic imaging. Lymphoscintigraphy, using technetium 99m (99mTc) based radiotracers along with single photon emission computed tomography/ computed tomography (SPECT/CT), holds a vital role in the identification of sentinel lymph nodes to minimize the surgical morbidity from extensive lymph node dissections. While not yet standard for gynecologic malignancies, promising therapeutic nuclear medicine agents serve as specialized treatment options for patients with advanced or recurrent disease. This article aims to provide a comprehensive review on the nuclear medicine applications in gynecologic malignancies through the following objectives: 1) To describe the role of nuclear medicine in the initial staging, lymph node mapping, response assessment, and recurrence/surveillance imaging of common gynecologic cancers, 2) To review the limitations of 18F-FDG PET/CT and promising applications of 18F-FDG PET/MRI in gynecologic malignancy, 3) To underscore the promising theragnostic applications of nuclear medicine, 4) To highlight the current role of nuclear medicine imaging in gynecologic cancers as per the National Comprehensive Cancer Network (NCCN), European Society of Surgical Oncology (ESGO), and European Society of Medical Oncology (ESMO) guidelines.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Khessib T, Jha P, Davidzon GA, et al. Nuclear Medicine and Molecular Imaging Applications in Gynecologic Malignancies: A Comprehensive Review. Semin Nucl Med. 2024. PMID: 38342655. doi:10.1053/j.semnuclmed.2024.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。